130 related articles for article (PubMed ID: 3649341)
1. A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
Hilfenhaus J; Geiger H; Lemp J; Hung CL
J Biol Stand; 1987 Jul; 15(3):251-63. PubMed ID: 3649341
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
Hilfenhaus J; Gregersen JP
Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety of blood products with respect to human immunodeficiency virus infection by using an HTLV-I-infected cell line (SKT-1B).
Koito A; Shirono K; Suto H; Matsushita S; Hattori T; Takatsuki K
Jpn J Cancer Res; 1987 Apr; 78(4):365-71. PubMed ID: 2884206
[TBL] [Abstract][Full Text] [Related]
5. Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations.
Tersmette M; de Goede RE; Over J; de Jonge E; Radema H; Lucas CJ; Huisman HG; Miedema F
Vox Sang; 1986; 51(3):239-43. PubMed ID: 3643679
[TBL] [Abstract][Full Text] [Related]
6. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.
Nowak T; Gregersen JP; Klockmann U; Cummins LB; Hilfenhaus J
J Med Virol; 1992 Mar; 36(3):209-16. PubMed ID: 1314286
[TBL] [Abstract][Full Text] [Related]
7. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1985; 35(11):1617-9. PubMed ID: 3004516
[TBL] [Abstract][Full Text] [Related]
8. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.
Hilfenhaus J; Herrmann A; Mauler R; Prince AM
Vox Sang; 1986; 50(4):208-11. PubMed ID: 3014743
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of retroviruses in biologicals manufactured for human use.
Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
12. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
13. Safety of human blood products: inactivation of retroviruses by heat treatment at 60 degrees C.
Hilfenhaus J; Mauler R; Friis R; Bauer H
Proc Soc Exp Biol Med; 1985 Apr; 178(4):580-4. PubMed ID: 2984690
[TBL] [Abstract][Full Text] [Related]
14. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
Dichtelmüller H; Rudnick D; Breuer B; Gänshirt KH
Biologicals; 1993 Sep; 21(3):259-68. PubMed ID: 8117439
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Mauler R; Merkle W; Hilfenhaus J
Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of viruses in therapeutic products derived from human plasma.
Mitra G; Dobkin MB; Louie RE; Mozen MM
Am J Med; 1988 Jun; 84(6A):87-90. PubMed ID: 2837900
[TBL] [Abstract][Full Text] [Related]
17. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
[TBL] [Abstract][Full Text] [Related]
18. [HIV safety of commercially produced human plasma proteins].
Hilfenhaus J
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():84-8. PubMed ID: 8000262
[TBL] [Abstract][Full Text] [Related]
19. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
Burnouf T
Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
[TBL] [Abstract][Full Text] [Related]
20. Effective inactivation of a wide range of viruses by pasteurization.
Gröner A; Broumis C; Fang R; Nowak T; Popp B; Schäfer W; Roth NJ
Transfusion; 2018 Jan; 58(1):41-51. PubMed ID: 29148053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
